Levomenol
Based on 1 Customer Validation
Levomenol ((-)-α-Bisabolol), a monocyclic sesquiterpene alcohol, exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. Levomenol also has neuroprotective effects and prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Levomenol attenuates nociceptive behaviour and central sensitisation in a rodent model of trigeminal neuropathic pain. Orally active.
For research use only. We do not sell to patients.
- Purity: 99.22%
- CAS No.: 23089-26-1
- Formula: C15H26O
- Molecular Weight:222.37
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
73 μM
Compound: 1
|
Inhibition of IFNgamma-induced STAT3 activation in human HeLa cells expressing p4xM67-tk-Luc treated 30 mins before TNFalpha challenge measured after 6 hrs
Inhibition of IFNgamma-induced STAT3 activation in human HeLa cells expressing p4xM67-tk-Luc treated 30 mins before TNFalpha challenge measured after 6 hrs
|
[PMID: 22309250] |
| HT-29 | GI50 |
>100 μM
Compound: alpha-bisabolol
|
Cytotoxicity against human HT-29 cells by sulforhodamine B assay
Cytotoxicity against human HT-29 cells by sulforhodamine B assay
|
[PMID: 20413188] |
| K562 | GI50 |
6.37 μM
Compound: alpha-bisabolol
|
Cytotoxicity against human K562 cells by sulforhodamine B assay
Cytotoxicity against human K562 cells by sulforhodamine B assay
|
[PMID: 20413188] |
| Leukemia cell | IC50 |
14 μM
Compound: BISA
|
Cytotoxicity against ALL/AML patient derived primary leukemia cells after 24 hrs by LDH release assay
Cytotoxicity against ALL/AML patient derived primary leukemia cells after 24 hrs by LDH release assay
|
[PMID: 30096653] |
| MCF7 | GI50 |
>100 μM
Compound: alpha-bisabolol
|
Cytotoxicity against human MCF7 cells by sulforhodamine B assay
Cytotoxicity against human MCF7 cells by sulforhodamine B assay
|
[PMID: 20413188] |
| NCI-H460 | GI50 |
>100 μM
Compound: alpha-bisabolol
|
Cytotoxicity against human NCI-H460 cells by sulforhodamine B assay
Cytotoxicity against human NCI-H460 cells by sulforhodamine B assay
|
[PMID: 20413188] |
| NIH3T3 | GI50 |
84 μg/mL
Compound: 2
|
Growth inhibition of mouse 3T3 cells
Growth inhibition of mouse 3T3 cells
|
[PMID: 11678668] |
| OVCAR-3 | GI50 |
>100 μM
Compound: alpha-bisabolol
|
Cytotoxicity against human OVCAR-3 cells by sulforhodamine B assay
Cytotoxicity against human OVCAR-3 cells by sulforhodamine B assay
|
[PMID: 20413188] |
| UACC-62 | GI50 |
>100 μM
Compound: alpha-bisabolol
|
Cytotoxicity against human UACC62 cells by sulforhodamine B assay
Cytotoxicity against human UACC62 cells by sulforhodamine B assay
|
[PMID: 20413188] |
(-)-α-bisabolol exerts anti-inflammatory effects by reducing astrogliosis, MPO activity, and TNF-α and iNOS production[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 23089-26-1
-
Appearance Liquid (Density: 0.9211 g/cm3)
-
Molecular Weight 222.37
-
Formula C15H26O
-
Color Colorless to light yellow
-
SMILES
C[C@@](O)([C@@]1([H])CCC(C)=CC1)CC/C=C(C)/C
-
Synonyms
(-)-α-Bisabolol
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (449.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (11.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fernandes MYD, et al. (-)-α-bisabolol prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Eur J Pharmacol. 2019 Jan 5;842:270-280. [Content Brief]
[2]. Melo LT, et al. (-)-α-Bisabolol reduces nociception and trigeminal central sensitisation in acute orofacial neuropathic pain induced by infraorbital nerve injury. Life Sci. 2019 Jun 15;227:122-128. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.4970 mL | 22.4850 mL | 44.9701 mL | 112.4252 mL |
| 5 mM | 0.8994 mL | 4.4970 mL | 8.9940 mL | 22.4850 mL | |
| 10 mM | 0.4497 mL | 2.2485 mL | 4.4970 mL | 11.2425 mL | |
| 15 mM | 0.2998 mL | 1.4990 mL | 2.9980 mL | 7.4950 mL | |
| 20 mM | 0.2249 mL | 1.1243 mL | 2.2485 mL | 5.6213 mL | |
| 25 mM | 0.1799 mL | 0.8994 mL | 1.7988 mL | 4.4970 mL | |
| 30 mM | 0.1499 mL | 0.7495 mL | 1.4990 mL | 3.7475 mL | |
| 40 mM | 0.1124 mL | 0.5621 mL | 1.1243 mL | 2.8106 mL | |
| 50 mM | 0.0899 mL | 0.4497 mL | 0.8994 mL | 2.2485 mL | |
| 60 mM | 0.0750 mL | 0.3748 mL | 0.7495 mL | 1.8738 mL | |
| 80 mM | 0.0562 mL | 0.2811 mL | 0.5621 mL | 1.4053 mL | |
| 100 mM | 0.0450 mL | 0.2249 mL | 0.4497 mL | 1.1243 mL |
Levomenol Related Classifications
HY-N6967 Related Classifications
Powered by Bioz